Skip to main content

Everest Approved for China Phase II trial of Trodelvy® in TROP-2 Cancers

Shanghai 's Everest Medicines said it is approved to conduct a China Phase II trial of Trodelvy® in patients with cancers that have high TROP-2 expression. Everest plans to enroll 180 patients with esophageal squamous cell carcinoma, gastric cancer and cervical cancer. In 2019, Everest acquired Greater China rights to Trodelvy in an agreement worth up to $835 million from Immunomedics, which was bought by Gilead. Last year, Everest began a registrational China Phase IIb trial of the candidate to treat metastatic triple-negative breast cancer. More details.... Stock Symbols: (HK: 1952) (NSDQ: GILD) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.